Thumbnail   OPUS
June 3, 2025

Opus’ LYNX-2 Phase III Trial Hits Primary Endpoint for Post-LASIK Night Vision Treatment

Opus’ phentolamine eye drops hit the LYNX-2 letter-gain target on mesopic low contrast distance visual acuity.  Opus Genetics (North Carolina,…

Discover our fascinating content at issuu

explore